Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study

Table 4 Common AEs (occurring in 5 % of patients or more)^a

AE, n (%)	Daclizumab 150 mg SC
AE, n (%)	(N = 410)
MS relapse	89 (22)
Nasopharyngitis	51 (12)
Upper respiratory tract infection	49 (12)
Increased ALT	37 (9)
Pharyngitis	35 (9)
Headache	33 (8)
Urinary tract infection	31 (8)
Back pain	29 (7)
Increased AST	28 (7)
Rash	27 (7)
Diarrhea	22 (5)
Allergic dermatitis	21 (5)
Viral respiratory tract infection	20 (5)
Bronchitis	19 (5)
Oral herpes	19 (5)

AE Adverse event, ALT Alanine aminotransferase, AST Aspartate aminotransferase, MS Multiple sclerosis, SC Subcutaneous
^aAEs in ≥5 % of patients by Medical Dictionary for Regulatory Activities Preferred Term

ISSN: 1471-2377